1997 until 2006. Dr. Boger served as Vertex's Chief Scientific Officer from

1989 until May 1992, and has been a Director since Vertex's inception. Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Departmentof Biophysical Chemistry. Dr.

Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University

Prior to Atlas Venture, Bruce was a Principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm. He focused on the firm's private equity activities, ranging from early stage venture capital through late stage buyouts. Prior to joining Caxton Health, he was an Associate Principal at McKinsey & Company, a global strategic management consulting firm, where he focused on R&D productivity, corporate strategy, and business development issues for several major biopharmaceutical companies. While at McKinsey, he also co-led the Firm's international scholars recruiting efforts.

Bruce sits on the Board of Zafgen and works closely with Atlas Venture portfolio companies ARCA Discovery, Archemix, Dynogen, Prestwick and NxStageMedical.

As a British Marshall Scholar, Bruce earned a Doctorate in Molecular Immunology from the Oxford University's Nuffield Department of Medicine and the Weatherall Institute of Molecular Medicine. His research focused on viral and tumor immune surveillance, and how the immune system responds to intracellular pathogenesis. During his graduate studies at Oxford, he also received the Overseas Research Fellowship and served as junior dean of Trinity College. Prior to graduate studies, he worked on President Clinton's Domestic Policy Council in the National Office of AIDS Policy. He received a Bachelor of Science degree with highest honors in Biochemistry from the Pennsylvania State University, where he was an Evan Pugh Scholar. 

Bill initially joined Boston Scientific in marketing to help launch TAXUS, the company's billion dollar drug-eluting stent. He has since become a Senior Manager within the Marketing Science group, an

internal strategy and market research team.

Bill has a BA from Middlebury College and an MBA from Harvard Business School.

Companies in which Dr. Galakatos has recently led financings include Affymax (spinout from GSK), Aveo, Critical Therapeutics (NASDAQ:CRTX), Hypnion, Portola (spinout from Millennium), Syrrx (acquired by Takeda), and TransForm (acquired by J&J).

• Noven Pharmaceuticals, Inc. -- Generic transdermal patches
• Vernalis plc -- Frova^® for the acute treatment of migraine headaches in adults
• Orexo AB -- Rapinyl^™ for breakthrough cancer pain
• DURECT Corporation -- Transdermal sufentanil patch for moderate-to-severe chronic pain
• ProEthic Pharmaceuticals, Inc.—Topical ketoprofen patch for acute pain associated with soft-tissue injuries
• ZARS Pharma, Inc. – Topical local anesthetic patch for superficial venous access.

Previously (1994-2000), Dr. Marshak was Senior Vice President and Chief Scientific Officer for Osiris Therapeutics, Inc., a U.S. biotechnology company developing adult stem cell products for the regeneration of diseased or damaged tissues. He was previously (1986-1995) Senior Staff Investigator at the Cold Spring Harbor Laboratory, Long Island, New York, where he and the members of his laboratory conducted research in signal transduction, cellular growth control, and differentiation. Dr. Marshak was concurrently (1987-1994) Assistant Professor, School of Medicine, State University of New York at Stony Brook, where he taught graduate biochemistry.

Dr. Marshak received his B.A. from Harvard University, Cambridge, Massachusetts, in Biochemistry & Molecular Biology, and his Ph.D. from The Rockefeller University, New York City, in Biochemistry & Cell Biology. He did postdoctoral research in Pharmacology at Vanderbilt University School of Medicine, Nashville, Tennessee, and at the National Institutes of Health, Bethesda, Maryland. Dr. Marshak has received several awards for scientific and academic achievements. He is also an inventor on six issued U.S. patents.

Dr. Marshak has extensive research experience in the growth control of human cells. Dr. Marshak is author of more than 100 scientific publications, including one textbook, and he has been editor of five monographs. The most recent monograph, Stem Cell Biology, was published in 2001 by The Cold Spring Harbor Laboratory Press.

Prior to joining Deloitte in November 2003, he worked as an independent consultant advising the executive board of a 400 person start-up, in the automotive services space for Cummins Inc. in India. He has worked with the Net Solutions Group at Novell Inc. in Boston, leading a joint go-to-market with Intel Inc. and setting up a technology showcase laboratory for Novell Inc. Rahul is a co-founder of a successful retail security solutions providing company, StopLift, Inc., that leverages facial recognition technologies and outsourcing to prevent shoplifting. He also worked at Cummins Inc. in Columbus IN as an Assembly and Test Engineer from March 1999 to August 2001, participating in a corporate strategy project to decide on the independence of Cummins Inc., leading supply chain management initiatives across the USA, UK, Mexico, India and China, heading new manufacturing systems design and implementation, and leading new product introduction programs for the fuel systems business.

Rahul attended Harvard Business School, where he graduated MBA with Distinction in 2003. Additionally he has an MS in Manufacturing Systems Engineering from the University of Wisconsin-Madison, and a BE in Mechanical Engineering from the University of Pune, India.

joining Tenet's Leadership Development Program, Sarah worked at St. Vincent Hospital in Worcester, MA and then accepted a position at Tenet's Corporate office where she led the development of the company's Balanced Scorecard. Before attending HBS, Sarah was an investment banker at JP Morgan and worked

for private equity firm JLL. As a private equity associate, she evaluated many healthcare investment opportunities, and helped form IASIS Healthcare.

In 1980, Dr. Navia established the first industrial macromolecular structure laboratory in the U.S., at Merck & Co., Inc., where he worked on the structures of human neutrophil elastase (a drug target for emphysema) and of carbonic anhydrase (for ocular hypertension and glaucoma). From 1989 to 1997, Dr. Navia was Vice-President and Senior Scientist at Vertex Pharmaceuticals in Cambridge, MA, where his interests in structure-based drug design were focused on studies of the FK506 binding protein and calcineurin (for immunosuppression), IL-1b converting enzyme (for inflammation), and HIV-1 protease (for AIDS), among other projects. In addition, Dr. Navia invented the cross-linked enzyme crystal (CLEC) catalyst technology that is currently under development across a broad front by Altus Biologics, a company that he co-founded.

Dr. Navia holds a B.A. degree in Physics from New York University (1967), an M.S. in Biophysics from the University of Chicago (1969) and a Ph.D. in Biophysics from the University of Chicago (1974).

Aaron Sandoski is the Managing Director of Norwich Ventures, a seed and early-stage venture capital firm specializing in the medical device industry.  Mr. Sandoski has a hands-on approach to investing and he is actively involved with the firm’s portfolio companies.  Currently, he serves on the boards of Syncro Medical Innovations and Genisent International. As the Managing Director, Mr. Sandoski is also responsible for the day-to-day activities of Norwich.

Prior to founding Norwich Ventures, Mr. Sandoski worked at DEKA R&D, the engineering think tank of Dean Kamen, where he helped develop partnerships and formulate business plans for emerging technologies. He has also worked in start-up operations where he helped launch a subsidiary of Express Scripts and helped launch a venture-backed payments company. Both companies were acquired in transactions totaling over $500 million. Mr. Sandoski began his career as a consultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to a rural hospital system. 

Mr. Sandoski takes an active interest in business and economic decision-making as well as teaching.  He is currently writing a book with a former colleague on the topic of business decision-making that will be published in 2007 by the Random House imprint, Crown Business.  In the past, he has taught introductory micro- and macro-economics at Harvard University as a Teaching Fellow where he won the Allyn Young Teaching Prize.

Mr. Sandoski earned an MBA from Harvard Business School and graduated summa cum laude from Dartmouth College with a double A.B. in Chemistry and Economics.  He lives in the Boston area with his wife and son.

Andrew’s consulting career has spanned strategy and business planning, business/technology enabled transformation and the management of change. His client base has included large multi-national pharmaceutical, biotechnology and medical supply organizations, reference laboratories, large academic health sciences centers, academic organizations, integrated delivery systems, provider organizations across the continuum of care, managed care companies, and numerous health technology organizations. He has successfully led the development of emerging technology strategies for world class health organizations, enterprise wide business transformation and re-engineering of academic medical centers in Canada and the US, facilitated numerous mergers and joint ventures and developed leading edge strategies for organizations in the provider, payer and life sciences sectors.

Some of Andrew’s clients include Partners Healthcare, Memorial Sloan Kettering, Northshore Long Island Jewish Health System, University of Pittsburgh Medical Center, Cleveland Clinic, and Hospital Corporation of America.